Literature DB >> 26113417

Deregulation of Fas ligand expression as a novel cause of autoimmune lymphoproliferative syndrome-like disease.

Schafiq Nabhani1, Sebastian Ginzel2, Hagit Miskin3, Shoshana Revel-Vilk4, Dan Harlev3, Bernhard Fleckenstein5, Andrea Hönscheid1, Prasad T Oommen1, Michaela Kuhlen1, Ralf Thiele6, Hans-Jürgen Laws1, Arndt Borkhardt1, Polina Stepensky4, Ute Fischer7.   

Abstract

Autoimmune lymphoproliferative syndrome is frequently caused by mutations in genes involved in the Fas death receptor pathway, but for 20-30% of patients the genetic defect is unknown. We observed that treatment of healthy T cells with interleukin-12 induces upregulation of Fas ligand and Fas ligand-dependent apoptosis. Consistently, interleukin-12 could not induce apoptosis in Fas ligand-deficient T cells from patients with autoimmune lymphoproliferative syndrome. We hypothesized that defects in the interleukin-12 signaling pathway may cause a similar phenotype as that caused by mutations of the Fas ligand gene. To test this, we analyzed 20 patients with autoimmune lymphoproliferative syndrome of unknown cause by whole-exome sequencing. We identified a homozygous nonsense mutation (c.698G>A, p.R212*) in the interleukin-12/interleukin-23 receptor-component IL12RB1 in one of these patients. The mutation led to IL12RB1 protein truncation and loss of cell surface expression. Interleukin-12 and -23 signaling was completely abrogated as demonstrated by deficient STAT4 phosphorylation and interferon γ production. Interleukin-12-mediated expression of membrane-bound and soluble Fas ligand was lacking and basal expression was much lower than in healthy controls. The patient presented with the classical symptoms of autoimmune lymphoproliferative syndrome: chronic non-malignant, non-infectious lymphadenopathy, splenomegaly, hepatomegaly, elevated numbers of double-negative T cells, autoimmune cytopenias, and increased levels of vitamin B12 and interleukin-10. Sanger sequencing and whole-exome sequencing excluded the presence of germline or somatic mutations in genes known to be associated with the autoimmune lymphoproliferative syndrome. Our data suggest that deficient regulation of Fas ligand expression by regulators such as the interleukin-12 signaling pathway may be an alternative cause of autoimmune lymphoproliferative syndrome-like disease. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26113417      PMCID: PMC4800681          DOI: 10.3324/haematol.2014.114967

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  50 in total

1.  Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop.

Authors:  Joao B Oliveira; Jack J Bleesing; Umberto Dianzani; Thomas A Fleisher; Elaine S Jaffe; Michael J Lenardo; Frederic Rieux-Laucat; Richard M Siegel; Helen C Su; David T Teachey; V Koneti Rao
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

2.  Inflammatory cytokines determine the susceptibility of human CD8 T cells to Fas-mediated activation-induced cell death through modulation of FasL and c-FLIP(S) expression.

Authors:  Anna von Rossum; Randall Krall; Nichole K Escalante; Jonathan C Choy
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

3.  Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation.

Authors:  Aude Magerus-Chatinet; Bénédicte Neven; Marie-Claude Stolzenberg; Cécile Daussy; Peter D Arkwright; Nina Lanzarotti; Catherine Schaffner; Sophie Cluet-Dennetiere; Filomeen Haerynck; Gérard Michel; Christine Bole-Feysot; Mohammed Zarhrate; Isabelle Radford-Weiss; Serge P Romana; Capucine Picard; Alain Fischer; Frédéric Rieux-Laucat
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

4.  A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation.

Authors:  Bénédicte Neven; Aude Magerus-Chatinet; Benoit Florkin; Delphine Gobert; Olivier Lambotte; Lien De Somer; Nina Lanzarotti; Marie-Claude Stolzenberg; Brigitte Bader-Meunier; Nathalie Aladjidi; Christophe Chantrain; Yves Bertrand; Eric Jeziorski; Guy Leverger; Gérard Michel; Felipe Suarez; Eric Oksenhendler; Olivier Hermine; Stéphane Blanche; Capucine Picard; Alain Fischer; Frédéric Rieux-Laucat
Journal:  Blood       Date:  2011-09-01       Impact factor: 22.113

5.  Control of Mycobacterium tuberculosis growth by activated natural killer cells.

Authors:  C Guerra; K Johal; D Morris; S Moreno; O Alvarado; D Gray; M Tanzil; D Pearce; V Venketaraman
Journal:  Clin Exp Immunol       Date:  2012-04       Impact factor: 4.330

6.  Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation.

Authors:  Masatoshi Takagi; Kunihiro Shinoda; Jinhua Piao; Noriko Mitsuiki; Mari Takagi; Kazuyuki Matsuda; Hideki Muramatsu; Sayoko Doisaki; Masayuki Nagasawa; Tomohiro Morio; Yoshihito Kasahara; Kenichi Koike; Seiji Kojima; Akira Takao; Shuki Mizutani
Journal:  Blood       Date:  2010-11-09       Impact factor: 22.113

7.  Autoimmune lymphoproliferative syndrome-like syndrome presented as lupus-like syndrome with mycobacterial joint infection evolved into the lymphoma.

Authors:  Young Hoon Hong; Choong Ki Lee
Journal:  Rheumatol Int       Date:  2008-09-27       Impact factor: 2.631

8.  Activated CD8+ T-effector/memory cells eliminate CD4+ CD25+ Foxp3+ T-suppressor cells from tumors via FasL mediated apoptosis.

Authors:  Mehmet O Kilinc; Rachael B Rowswell-Turner; Tao Gu; Lauren P Virtuoso; Nejat K Egilmez
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

9.  A framework for variation discovery and genotyping using next-generation DNA sequencing data.

Authors:  Mark A DePristo; Eric Banks; Ryan Poplin; Kiran V Garimella; Jared R Maguire; Christopher Hartl; Anthony A Philippakis; Guillermo del Angel; Manuel A Rivas; Matt Hanna; Aaron McKenna; Tim J Fennell; Andrew M Kernytsky; Andrey Y Sivachenko; Kristian Cibulskis; Stacey B Gabriel; David Altshuler; Mark J Daly
Journal:  Nat Genet       Date:  2011-04-10       Impact factor: 38.330

10.  Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor.

Authors:  William McLaren; Bethan Pritchard; Daniel Rios; Yuan Chen; Paul Flicek; Fiona Cunningham
Journal:  Bioinformatics       Date:  2010-06-18       Impact factor: 6.937

View more
  6 in total

1.  Impaired IL-12- and IL-23-Mediated Immunity Due to IL-12Rβ1 Deficiency in Iranian Patients with Mendelian Susceptibility to Mycobacterial Disease.

Authors:  Nioosha Nekooie-Marnany; Caroline Deswarte; Vajiheh Ostadi; Bahram Bagherpour; Elaheh Taleby; Mazdak Ganjalikhani-Hakemi; Tom Le Voyer; Hamid Rahimi; Jérémie Rosain; Zahra Pourmoghadas; Saba Sheikhbahaei; Razieh Khoshnevisan; Daniel Petersheim; Daniel Kotlarz; Christoph Klein; Stéphanie Boisson-Dupuis; Jean-Laurent Casanova; Jacinta Bustamante; Roya Sherkat
Journal:  J Clin Immunol       Date:  2018-09-25       Impact factor: 8.317

Review 2.  Mendelian susceptibility to mycobacterial disease: 2014-2018 update.

Authors:  Jérémie Rosain; Xiao-Fei Kong; Ruben Martinez-Barricarte; Carmen Oleaga-Quintas; Noé Ramirez-Alejo; Janet Markle; Satoshi Okada; Stéphanie Boisson-Dupuis; Jean-Laurent Casanova; Jacinta Bustamante
Journal:  Immunol Cell Biol       Date:  2018-10-25       Impact factor: 5.126

3.  Stabilized β-Catenin Ameliorates ALPS-Like Symptoms of B6/lpr Mice.

Authors:  Xiaoxie Xu; Jun Huang; Mei Zhao; Huanpeng Chen; Jinhua Mo; Xiaoqing Zhou; Qiao Su; Bolan Yu; Zhaofeng Huang
Journal:  J Immunol Res       Date:  2017-11-09       Impact factor: 4.818

Review 4.  Flow Cytometry Contributions for the Diagnosis and Immunopathological Characterization of Primary Immunodeficiency Diseases With Immune Dysregulation.

Authors:  Otavio Cabral-Marques; Lena F Schimke; Edgar Borges de Oliveira; Nadia El Khawanky; Rodrigo Nalio Ramos; Basel K Al-Ramadi; Gesmar Rodrigues Silva Segundo; Hans D Ochs; Antonio Condino-Neto
Journal:  Front Immunol       Date:  2019-11-26       Impact factor: 7.561

Review 5.  Cytolytic CD4+ and CD8+ Regulatory T-Cells and Implications for Developing Immunotherapies to Combat Graft-Versus-Host Disease.

Authors:  Sara Bolivar-Wagers; Jemma H Larson; Sujeong Jin; Bruce R Blazar
Journal:  Front Immunol       Date:  2022-04-12       Impact factor: 8.786

Review 6.  A Variety of Alu-Mediated Copy Number Variations Can Underlie IL-12Rβ1 Deficiency.

Authors:  Jérémie Rosain; Carmen Oleaga-Quintas; Caroline Deswarte; Hannah Verdin; Stéphane Marot; Garyfallia Syridou; Mahboubeh Mansouri; S Alireza Mahdaviani; Edna Venegas-Montoya; Maria Tsolia; Mehrnaz Mesdaghi; Liudmyla Chernyshova; Yuriy Stepanovskiy; Nima Parvaneh; Davood Mansouri; Sigifredo Pedraza-Sánchez; Anastasia Bondarenko; Sara E Espinosa-Padilla; Marco A Yamazaki-Nakashimada; Alejandro Nieto-Patlán; Gaspard Kerner; Nathalie Lambert; Corinne Jacques; Emilie Corvilain; Mélanie Migaud; Virginie Grandin; María T Herrera; Fabienne Jabot-Hanin; Stéphanie Boisson-Dupuis; Capucine Picard; Patrick Nitschke; Anne Puel; Frederic Tores; Laurent Abel; Lizbeth Blancas-Galicia; Elfride De Baere; Christine Bole-Feysot; Jean-Laurent Casanova; Jacinta Bustamante
Journal:  J Clin Immunol       Date:  2018-07-11       Impact factor: 8.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.